Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLX-008
- Development stage
- Preclinical
- Lead developer
- Easywell Biomedicals
- Modality
- Small Molecules
01
Overview
TLX-008 is an investigational small molecule drug candidate developed by Easywell Biomedicals, a biotechnology company based in Taiwan. It is specifically being developed for the prevention of Pneumocystis pneumonia (PCP), a serious opportunistic infection caused by the fungus *Pneumocystis jirovecii*. PCP primarily affects individuals with compromised immune systems, such as those living with HIV/AIDS, organ transplant recipients, or patients undergoing intensive chemotherapy. TLX-008 is part of Easywell's infectious disease pipeline and is intended to provide a prophylactic option to reduce the incidence of fungal pneumonia in high-risk populations.
Beyond the preview
Go deeper on TLX-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLX-008.